https://orcid.org/0000-0001-7272-8824
References
- Barman-Aksözen, J., M. Nydegger, X. Schneider-Yin, and A.-E. Minder. 2020. “Increased Phototoxic Burn Tolerance Time and Quality of Life in Patients with Erythropoietic Protoporphyria Treated with Afamelanotide – A Three Years Observational Study.” Orphanet Journal of Rare Diseases 15 (1): 1–8. doi:10.1186/s13023-020-01505-6.
- Charlton, V. 2020. “NICE and Fair? Health Technology Assessment Policy under the UK’s National Institute for Health and Care Excellence, 1999-2018.” Health Care Analysis 28 (3): 193. doi:10.1007/s10728-019-00381-x.
- Equality Act. 2010. “Definition of disability under the Equality Act 2010.” Accessed April 4, 2021. https://www.gov.uk/definition-of-disability-under-equality-act-2010
- Falchetto, R. 2020. “The Patient Perspective: A Matter of Minutes.” The Patient 13 (1): 1–6. doi:10.1007/s40271-019-00399-2.
- Langendonk, J. G., M. Balwani, K. E. Anderson, H. L. Bonkovsky, A. V. Anstey, D. M. Bissel, J. Bloomer, et al. 2015. “Afamelanotide for Erythropoietic Protoporphyria.” The New England Journal of Medicine 373 (1): 48–59. doi:10.1056/NEJMoa1411481.
- McPherson, S., and P. Beresford. 2019. “Semantics of Patient Choice: How the UK National Guideline for Depression Silences Patients.” Disability & Society 34 (3): 491–497. doi:10.1080/09687599.2019.1589757.
- Naik, H., S. Shenbagam, A. M. Go, and M. Balwani. 2019. “Psychosocial Issues in Erythropoietic Protoporphyria – The Perspective of Parents, Children, and Young Adults: A Qualitative Study.” Molecular Genetics and Metabolism 128 (3): 314–319. doi:10.1016/j.ymgme.2019.01.023.
- NICE. 2018a. “Afamelanotide for Treating Erythropoietic Protoporphyria.” Final evaluation document. May 2018. https://www.nice.org.uk/guidance/gid-hst10009/documents/final-evaluation-determination-document
- NICE. 2018b. “Advice on Afamelanotide for Treating Erythropoietic Protoporphyria [ID927].” Decision of the panel. London. 2018. https://www.nice.org.uk/guidance/gid-hst10009/documents/appeal-decision
- Rufener, E. A. 1987. “Erythropoietic Protoporphyria: A Study of Its Psychosocial Aspects.” British Journal of Dermatology 116 (5): 703–708. doi:10.1111/j.1365-2133.1987.tb05904.x.
- Rutter, K. J., I. Ashraf, L. Cordingley, and L. E. Rhodes. 2020. “Quality of Life and Psychological Impact in the Photodermatoses: A Systematic Review.” The British Journal of Dermatology 182 (5): 1092–1102. doi:10.1111/bjd.18326.
- Schlander, M. 2008. “The Use of Cost-Effectiveness by the National Institute for Health and Clinical Excellence (NICE): No(t Yet an) Exemplar of a Deliberative Process.” Journal of Medical Ethics 34 (7): 534–539. doi:10.1136/jme.2007.021683.